جست‌وجوی استاد و پژوهشگر

Samuel Norbert Breitمشاهده پروفایل

استاد

• Immunology
• Rheumatology
• Connective Tissue Diseases
• +۹ مورد دیگر

Conjoint Professor Samuel Norbert Breit is a Clinical Immunologist and Immunopathologist at St Vincent's Hospital Sydney and a Professor of Medicine at the University of New South Wales. He heads the Inflammation and Cytokine Biology Research Program at St Vincent's Centre of Applied Medical Research, where he leads a team investigating the biology and therapeutic applications of MIC-1/GDF15 and its receptor GFRAL. Professor Breit's educational background includes: MBBS (Bachelor of Medicine, Bachelor of Surgery) MD (Doctor of Medicine) FRACP (Fellow of the Royal Australasian College of Physicians) FRCPA (Fellow of the Royal College of Pathologists of Australasia) With a career-long interest in biomedical research, Professor Breit has established himself as an international leader in the study of GDF15, which his laboratory first cloned and characterized. His research has focused on understanding the biology of this cytokine, particularly its role as a metabolic regulator. Professor Breit's group has spearheaded the investigation of MIC-1/GDF15, discovering its importance in appetite regulation, metabolism, inflammation, and immunity. His seminal work on the role of MIC-1/GDF15 in cancer anorexia/cachexia and appetite regulation earned recognition from the NHMRC through inclusion in their 'Ten best projects 2011' publication. Professor Breit's research program currently focuses on elucidating the mechanisms by which GDF15 exerts its effects through three main avenues: (1) aspects of the basic biology of the GDF15-GFRAL pathway, (2) the means by which this pathway regulates metabolism, and (3) the mechanisms by which it influences immune and inflammatory responses. His work has significant therapeutic implications for conditions including obesity, cancer-associated syndromes, inflammatory diseases, and cardiovascular disorders. His laboratory's discoveries have been licensed to several major international companies for applications in cancer and cardiovascular disease diagnosis and management, as well as for therapeutic development targeting inflammatory diseases, obesity, and cancer-associated syndromes. Professor Breit has been recognized for his contributions to medical science: NHMRC 'Ten best projects 2011' for his seminal studies on MIC-1/GDF15 in cancer anorexia/cachexia and appetite regulation Professor Breit maintains an active research program involving post-doctoral scientists and PhD students. He supervises multiple PhD projects focused on the role of MIC-1/GDF15 in regulating appetite, sculpting metabolism to resist obesity and inflammation, and regulating inflammatory responses and tumor immunity. He has a long track record of project grant support from various funding bodies, enabling his team to pursue innovative research at the intersection of immunology, metabolism, and inflammation. As head of the Inflammation and Cytokine Biology Research Program at St Vincent's Centre of Applied Medical Research, Professor Breit leads a multidisciplinary team comprising immunologists, molecular biologists, and clinical researchers. The program maintains state-of-the-art facilities for molecular biology, cell culture, and animal studies, allowing for comprehensive investigation of the GDF15-GFRAL signaling pathway from basic mechanisms to potential clinical applications.

Sebastian Albinssonمشاهده پروفایل

مدرس ارشد

• Vascular Physiology
• Smooth Muscle Biology
• MicroRNA Research
• +۳ مورد دیگر

Sebastian Albinsson is a Senior Lecturer and Molecular Vascular Physiology Researcher at Lund University's Faculty of Medicine. He holds roles as Research Team Manager, Course Director, and Principal Investigator within the EXODIAB: Excellence of Diabetes Research in Sweden initiative. His work contributes to UN Sustainable Development Goals focused on health and well-being. Research Interests: Albinsson specializes in vascular physiology, smooth muscle biology, and the role of microRNAs in cardiovascular disease. His research explores hypertension mechanisms, aneurysm development, and molecular pathways regulating vascular smooth muscle function. Key focuses include YAP/TAZ signaling, actin cytoskeleton dynamics, and transcription factor-driven processes in vascular pathology. Recent Article Trends: Recent work emphasizes genome sequencing in heart failure, YAP/TAZ regulation in vascular mechanotransduction, and microRNA-driven lipid accumulation. These studies highlight translational applications in precision medicine and disease prevention. Grants & Projects: Exploring the relationship between metabolic vascular disease, smooth muscle mechanosensing and vascular ageing (2025–2026) Kan blodkärlens sträcksenor skydda mot aneurysm? (2024–2026) Advising: Supervised 8 research works, focusing on vascular biology and molecular mechanisms. Labs/Teams: Active in EXODIAB and the Molecular Vascular Physiology group, collaborating internationally on cardiovascular and diabetes research.

Yuan Maمشاهده پروفایل

استادیار

• Chemical Biology
• Biochemistry
• Analytical Chemistry
• +۷ مورد دیگر

Yuan Ma is an Assistant Professor at Rice University's Department of Chemistry, holding the Kenneth S. Pitzer-Schlumberger Junior Faculty Chair and Norman Hackerman-Welch Young Investigator titles. She leads the Ma Lab, focused on developing chemical biology tools for interdisciplinary research in chemistry, biology, and biomedical applications. Her work spans RNA/protein studies, disease biomarkers, and nanomedicine for early detection and therapy. Education: B.A. in Materials Physics from Nanjing University (2012), Ph.D. in Chemistry from Shanghai Jiao Tong University (co-advised by Professors Deyue Yan, Xinyuan Zhu, and Chuan Zhang), followed by postdoctoral research at the University of Illinois at Urbana-Champaign and the University of Texas at Austin under Professor Yi Lu. Research Interests: Chemical biology tools for in situ RNA/protein analysis, glycoRNA and epigenetic RNA investigations, RNA/protein disease mechanisms, and disease early detection via biomarkers. The lab’s tools advance both fundamental knowledge and translational science. Recent achievements include developing ARPLA for glycoRNA spatial imaging, aptamer-based sensors, and targeted cancer therapies. Awards include the Provost Early Career Fellowship and Leading Edge Fellowship. The lab is affiliated with Rice’s Systems, Synthetic, and Physical Biology (SSPB) Graduate Program and the SynthX Center. Advising: Supervises graduate students (e.g., Haoyue Dong, Yingying Zhu) and postdocs (e.g., Xiangli Shao, Xinmin Zhang). Collaborates on projects like nucleolin aptamer-mediated drug release and stapled aptamers for bone diseases. Active in training future scientists through Rice’s graduate and undergraduate programs. Labs/Teams: Ma Lab at BioScience Research Collaborative (BRC), emphasizing interdisciplinary collaboration and diversity.

• Medicinal Chemistry
• Organic Synthesis
• Drug Discovery
• +۳ مورد دیگر

Dr. Stephen Hobson is a Lecturer in the Department of Chemistry within Newcastle University's School of Natural and Environmental Sciences, actively contributing to medicinal chemistry and organic synthesis research. His collaborative work spans multiple high-impact publications in drug discovery and green chemistry. His research focuses on targeted cancer therapeutics (kinase/bromodomain inhibitors), antimalarial drug development , and sustainable synthesis methods . Key projects include covalent NIK inhibitors for NF-κB pathway modulation, MDM2-p53 interaction disruptors, and continuous-flow oxidation catalysis. Recent publications (2015-2021) reveal expertise in fragment-based drug design , structure-activity relationship optimization , and flow chemistry applications . His work bridges chemical biology and translational medicine, with emphasis on selective targeting mechanisms and green chemistry principles. No scientific awards were documented in the source material. Hobson collaborates extensively across Newcastle's chemistry and medical research groups, evidenced by co-authorship with Professor Jane Endicott (cancer biology) and Dr. Michael Carroll (organic synthesis). While specific grant details aren't provided, his publication pattern indicates sustained funding for drug discovery and synthetic methodology projects. His laboratory work integrates medicinal chemistry (kinase/bromodomain targets), parasitology (antimalarial compounds), and flow chemistry engineering through partnerships with chemical engineering teams.

• Prostate Cancer Research
• Breast Cancer Research
• Molecular Biology
• +۷ مورد دیگر

Dr. Dominic Jones is a Researcher at Newcastle University, specializing in prostate and breast cancer biology, molecular mechanisms of hormone receptors, and transcriptional regulation. His work spans CRISPR engineering, RNA splicing, and pathway modulation. Research Focus: Hormonal oncology, gene regulation, and targeted cancer therapies. Collaborations: Extensive co-authorship with experts in prostate cancer, including Dr. Luke Gaughan, Professor Craig Robson, and Dr. Sirintra Nakjang. His contributions include defining splicing factor requirements for androgen receptor variants (2024), CRISPR-engineered cell lines for PARP inhibitor sensitivity (2019), and elucidating the role of Aurora A kinase in castrate-resistant models (2017). His research intersects molecular biology, genetics, and pharmacology to advance cancer treatments.

• Molecular Biology
• Biochemistry
• Medical Research
• +۵ مورد دیگر

Dr. Ian Logan is a Researcher at Newcastle University, specializing in molecular mechanisms related to prostate cancer and renal disease. His work focuses on androgen receptor signaling, epigenetic regulation, and ubiquitin-mediated pathways in cellular processes. Key collaborations with Professors Craig Robson, Neil Sheerin, and David Neal Extensive research in renal physiology, hypertension management, and prostate cancer therapeutics Research trends across 15 publications (2002-2022) highlight expertise in: Androgen receptor interactions with histone deacetylase and SMAD3 Mechanisms of renal fibrosis (SETD7, TGFβ signaling) Ubiquitin pathway modulation (MDM2, PIRH2, Usp12) Cancer cell apoptosis through Nutlin-3 and c-FLIP inhibition Sex/gender differences in disease outcomes (hypertension, COVID-19 mortality) His work spans interdisciplinary domains including biochemistry, genetics, nephrology, and oncology, with a focus on translational implications for kidney disease and prostate cancer.

• Molecular Biology
• Biochemistry
• Nutrition Science
• +۳ مورد دیگر

Ana Isabel Rojas González is a Full Professor in the Department of Molecular Biology and Biochemical Engineering at Universidad Pablo de Olavide. Her research focuses on the intersection of molecular biology, nutrition science, and diabetes, particularly investigating the role of transcription factors like GATA4 in liver fibrosis, pancreatic development, and metabolic regulation. She leads the NUTRITION AND DIABETES research group. University: Universidad Pablo de Olavide Department: Molecular Biology and Biochemical Engineering Research Group: Nutrition and Diabetes Education: PhD in Molecular Biology, University of Seville (2001) Thesis: Mechanisms of regulation of shsp gene expression during embryonic development Ana's research spans developmental gene regulation, metabolic diseases, and dietary interventions. Her work on GATA4 and GATA6 transcription factors explores their roles in pancreas specification, beta-cell function, and liver fibrosis mechanisms. She also investigates how maternal diets (e.g., olive oil) influence offspring metabolic health through epigenetic pathways. Research Trends: Her publications highlight transcriptional control of organogenesis, environmental impacts on glucose homeostasis (e.g., malathion exposure), and therapeutic potential of nuclear receptors (e.g., LRH-1) in islet survival. Recent studies focus on intergenerational metabolic programming and antidiabetic agents targeting signaling pathways. Labs & Teams: She contributes to the NUTRITION AND DIABETES research group and collaborates on doctoral programs in Biotechnology, Biomedicine, and Health Sciences.

Kurtis Buddenمشاهده پروفایل

پژوهشگر

• Diet
• Metabolism
• Gastrointestinal Microbiome
• +۹ مورد دیگر

Dr. Kurtis Budden is a Post Doctoral Researcher at the University of Newcastle, affiliated with the School of Biomedical Sciences and Pharmacy and the Priority Research Centre for Healthy Lungs. His research focuses on the interplay between diet, metabolism, and the gastrointestinal microbiome in chronic lung diseases, particularly COPD and asthma. Research Highlights: Investigates how microbial metabolites and dietary interventions (e.g., fiber, probiotics) modulate COPD pathogenesis. Explores the gut-lung axis and environmental exposures (e.g., bushfire particulates) in respiratory health. Conducts both fundamental and clinical research, including transcriptomic analyses and therapeutic target identification. Key Trends in Publications: Recent work emphasizes microbiome transplantation, lipid metabolism, and epithelial barrier dysfunction in COPD and asthma-COPD overlap. Studies often integrate multi-omics approaches and preclinical models. Scientific Awards: 2025 Best Presentation - COPD SIG (The Thoracic Society of Australia & New Zealand) 2024 Runner Up - Gut Top Paper 2022 TSANZ Past President's Scholarship 2020 Ann Woolcock Young Investigator Award Grants: Leads and collaborates on grants totaling $994,588, including NHMRC Synergy Grants and funding from the Hunter Medical Research Institute for microbiome studies in COPD and cystic fibrosis.

Jun Yuمشاهده پروفایل

استاد

• Vascular Biology
• Atherosclerosis
• Endoplasmic Reticulum Stress
• +۴ مورد دیگر

Jun Yu, MD, FAHA is a Professor and Vice Chair of Biomedical Education and Data Science at Temple University's Lewis Katz School of Medicine, with additional professorships in Cardiovascular Sciences and the Center for Metabolic Disease Research. His multidisciplinary roles span vascular biology, metabolic disease research, and biomedical data science. Dr. Yu's research focuses on molecular mechanisms of vascular remodeling, atherogenesis, and ER stress-related pathologies. Key interests include reticulon family proteins in plaque necrosis, autophagy-inflammation crosstalk, vascular fibrosis involving MKP5 signaling, and collateral artery remodeling in metabolic disease. His laboratory extensively employs mouse genetic models, cell biological approaches, and biochemical assays. Recent publication trends (2022-2025) emphasize natural compounds (Edgeworthia gardneri, saponins, flavonoids) for atherosclerosis and vascular inflammation, with growing focus on trained immunity, gut-microbiota interactions, and novel biomarkers (ELABELA, soluble prorenin receptor) for cardiovascular diseases. His work bridges molecular mechanisms with translational applications. Dr. Yu's laboratory maintains active collaborations across vascular biology, immunology, and pharmacology fields, with recent emphasis on macrophage polarization, T-cell subsets in atherosclerosis, and epigenetic regulation of vascular smooth muscle cells. His research program integrates advanced techniques including single-cell RNA-seq, metabolomics, and sophisticated murine disease models.

Paul Eggletonمشاهده پروفایل

استاد

• Innate and adaptive immunity
• Autoimmune diseases
• Neuroinflammation
• +۶ مورد دیگر

Dr. Paul Eggleton is an Honorary Professor of Immunology at the University of Exeter Medical School and Vice President of Immunology at Revolo Biotherapeutics . With academic affiliations spanning University of Oxford , Boston University , and University of Alberta , he has led groundbreaking research in innate immunity , neuroinflammation , and chaperone protein immunobiology . Trained at Royal Free Hospital School of Medicine and Royal College of Surgeons Postdoctoral work: MRC Immunochemistry Unit (Oxford), Boston University His work has redefined understanding of ER chaperones in immunomodulation, particularly calreticulin 's extracellular functions in cancer cell death and autoimmune pathogenesis. He co-discovered the lectin pathway of complement activation and identified CD20+ T cell subsets in multiple sclerosis and rheumatoid arthritis. Current research at UCB Pharma and Revolo Biotherapeutics focuses on: Neuroinflammation in CNS disorders Immunomodulatory peptides like IRL201104 Stress pathways (cGAS-STING) in neurodegeneration Scientific contributions: MRC and ARC funded fellowships Over 200 peer-reviewed publications Key discoveries in calnexin-Fabp5 complex , CD200 regulation , and oxidative autoantigen modifications His academic leadership included serving as Immunology Curriculum Lead (2008-2017) and establishing the 11th International Calreticulin Workshop. He supervises students like Emma Charlton and collaborates with teams across University of Alberta , Cambridge , and Oxford .

Chiara Boniniمشاهده پروفایل

استاد

• Immunotherapy
• Gene Therapy
• Hematological Malignancies
• +۳ مورد دیگر

Chiara Bonini is a Full Professor at Vita-Salute San Raffaele University in the Faculty of Medicine and Surgery , with a focus on Blood Diseases (MEDS-09/B) . She serves as Deputy Director of the Division of Immunology, Transplantation and Infectious Diseases Research at San Raffaele Hospital Scientific Institute, Milan, and leads the Experimental Hematology Unit there since 2008. 1994: MD, summa cum laude, University of Milan 1998: Hematology specialization, University of Pavia 1993: Intern, Memorial Sloan Kettering Cancer Center 1996-1998: Postdoctoral Fellow, Telethon Institute for Gene Therapy 1998-2000: Postdoctoral Fellow, Fred Hutchinson Cancer Research Center Her research centers on immunotherapy and gene therapy for cancer, particularly genetically modified T lymphocytes to enhance safety and efficacy in allogeneic stem cell transplantation. Key contributions include the first European-approved cell and gene therapy product for oncological diseases, developed through clinical trials like "HSV-tk suicide gene transfer" and "TK007 phase I-II study". Recent publications highlight advances in CAR T cell therapy for solid tumors, epigenetic regulation of engineered lymphocytes, and metabolic reprogramming of regulatory T cells. Her work spans hematological malignancies , autoimmune disorders , and tumor microenvironment manipulation . 2024-2025 articles : TGFβ inhibition, CAR T safety, autoimmune homeostasis, and metabolic T cell engineering 2025 courses : Hematology (6-year MD program), Blood and Immune System Diseases Notable awards include the Van Bekkum Award , Van Rood Award , and Basic Science Award from EBMT, alongside editorial roles in journals like Molecular Therapy and Human Gene Therapy . She actively reviews grants for organizations including the European Research Council and Cancer Research UK .

Helmut Albrechtمشاهده پروفایل

استاد

• Internal Medicine
• Infectious Diseases
• Immunology
• +۶ مورد دیگر

Helmut Albrecht, MD is Professor and Heyward Gibbs Distinguished Professor in Internal Medicine at the University of South Carolina School of Medicine Columbia . He leads research in the Division of USC Immunology Center and has served as Chair of the Department of Medicine for Prisma Health Medical Group. University of Hamburg, MD (1988) Residencies: University of Hamburg (1988), Emory University (2001) Fellowships: University of Hamburg (1995), Emory University (1999) Dr. Albrecht's research spans infectious diseases , HIV cardiovascular comorbidities , and telehealth implementation . He has led major clinical trials like REPRIEVE and PURPOSE 2, focusing on statin therapy for HIV patients and long-acting HIV prevention. HIV research dominates his work, with studies on telehealth adoption , antimicrobial stewardship , and viral immunology . Recent publications (2025) analyze telehealth features in rural HIV care, while 2022 work explores SARS-CoV-2 interactions with HIV. Scientific Awards : Heyward Gibbs Distinguished Professorship Advising : Mentored over 200 clinical researchers (unspecified names) Grants : National Institutes of Health, private foundations

• Immunology
• Parasitology
• Autoimmune Diseases
• +۳ مورد دیگر

A/Prof Sheila Donnelly is an Adjunct Associate Professor in the School of Life Sciences at the University of Technology Sydney (UTS). Her research focuses on host-parasite interactions, particularly exploring how helminth parasites manipulate host immune systems and translating this knowledge into autoimmune disease therapies. She holds a PhD in Virology from Trinity College Dublin and conducted postdoctoral work at the National University of Ireland Maynooth. Key research streams include the development of immunomodulatory peptides from helminths for treating conditions like multiple sclerosis and type 1 diabetes. Her work has led to discoveries such as the first parasite-derived protein independently activating macrophages without IL-4/IL-13 signaling. She has secured grants from the ARC, NHMRC, and JDRF, focusing on molecular mechanisms of parasite-host interactions and therapeutic applications. Dr. Donnelly has published extensively in high-impact journals and contributed to book editorships, including Antimicrobial Peptides: Utility Players in Innate Immunity . Her research also explores miRNA biomarkers for parasitic infections. Supervision of postgraduate students and involvement in commercialization efforts highlight her commitment to bridging basic science and clinical applications.

• Bacteriophage Mechanisms
• DNA Translocation
• Phage Evolutionary Genetics
• +۲ مورد دیگر

Ian J. Molineux is Professor of Molecular Biosciences at the University of Texas at Austin, where he leads research on bacteriophage infection mechanisms using phage T7 as a model system. His work combines genetics, biophysics, and structural biology to understand DNA translocation across cell envelopes and develop phage-based applications. The Molineux lab focuses on: 1) Motor protein-driven DNA transport during phage infection, 2) Evolutionary genetics of phage-host interactions, and 3) Phage therapy development. Research employs CRISPR technology, electron cryo-tomography, and in vitro reconstitution approaches to study nucleic acid translocation mechanisms. Key discoveries include characterization of the phage DNA injection apparatus and demonstration of transcription-driven genome internalization. Recent work explores phage engineering for therapeutic applications and fundamental studies of host-parasite coevolution. Molineux teaches courses in molecular genetics and mentors graduate students in interdisciplinary virology research.

Patrick Kehoeمشاهده پروفایل

استاد

• Alzheimer's Disease
• Vascular Dementia
• Cerebrovascular Hypertension
• +۴ مورد دیگر

Professor Patrick Kehoe is the Gestetner Professor of Translational Dementia Research at the University of Bristol's Bristol Medical School (THS) and Director of Research, Enterprise and Innovation at the Elizabeth Blackwell Institute. He holds a B.Sc. from Trinity College Dublin and a Ph.D. from Cardiff University, Wales. His work focuses on cerebrovascular hypertension, Alzheimer’s disease mechanisms, vascular cognitive impairment, and translational medicine. He leads studies on drug repurposing strategies targeting the renin-angiotensin system to mitigate dementia progression. Key research interests include genetic epidemiology of dementias, polygenic risk stratification, and drug efficacy trials such as the RADAR trial evaluating losartan’s role in Alzheimer’s pathology. He collaborates with institutions like the European Alzheimer’s Disease Consortium and the UK Biobank to investigate environmental and genetic risk factors. Recent articles emphasize Mendelian randomization analyses of antihypertensive drug repurposing, epigenetic biomarkers in Lewy body dementias, and cross-ancestry polygenic risk score applications. His work bridges basic science and clinical translation, addressing vascular contributions to neurodegeneration. He advises on dementia policy and clinical trial methodologies, contributing to consensus guidelines for decentralized trials and pharmacoeconomic evaluations of emerging therapies. His translational focus spans drug discovery pipelines, biomarker validation, and precision medicine approaches for at-risk populations.